451 related articles for article (PubMed ID: 18448188)
21. Steroid receptor expression in thymomas and thymic carcinomas.
Mimae T; Tsuta K; Takahashi F; Yoshida A; Kondo T; Murakami Y; Okada M; Takeuchi M; Asamura H; Tsuda H
Cancer; 2011 Oct; 117(19):4396-405. PubMed ID: 21437890
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.
Tawbi H; Thomas D; Lucas DR; Biermann JS; Schuetze SM; Hart AL; Chugh R; Baker LH
Oncologist; 2008 Apr; 13(4):459-66. PubMed ID: 18448562
[TBL] [Abstract][Full Text] [Related]
23. Thymic carcinoma with epidermal growth factor receptor gene mutations.
Yamaguchi H; Soda H; Kitazaki T; Tsukamoto K; Hayashi T; Kohno S
Lung Cancer; 2006 May; 52(2):261-2. PubMed ID: 16545487
[No Abstract] [Full Text] [Related]
24. Epidermal growth factor receptor structural alterations in gastric cancer.
Moutinho C; Mateus AR; Milanezi F; Carneiro F; Seruca R; Suriano G
BMC Cancer; 2008 Jan; 8():10. PubMed ID: 18199332
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors.
Tateyama H; Eimoto T; Tada T; Inagaki H; Hattori H; Takino H
Mod Pathol; 1997 Oct; 10(10):983-91. PubMed ID: 9346177
[TBL] [Abstract][Full Text] [Related]
26. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
J Surg Oncol; 2009 Jun; 99(7):433-8. PubMed ID: 19347882
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer.
Mammano E; Belluco C; Sciro M; Mencarelli R; Agostini M; Michelotto M; Marchet A; Nitti D
Anticancer Res; 2006; 26(5A):3547-50. PubMed ID: 17094480
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
[TBL] [Abstract][Full Text] [Related]
29. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-1 receptor expression in thymic malignancies.
Girard N; Teruya-Feldstein J; Payabyab EC; Riely GJ; Rusch VW; Kris MG; Zakowski MF
J Thorac Oncol; 2010 Sep; 5(9):1439-46. PubMed ID: 20736806
[TBL] [Abstract][Full Text] [Related]
31. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma.
Hirabayashi H; Fujii Y; Sakaguchi M; Tanaka H; Yoon HE; Komoto Y; Inoue M; Miyoshi S; Matsuda H
Int J Cancer; 1997 Nov; 73(5):639-44. PubMed ID: 9398039
[TBL] [Abstract][Full Text] [Related]
32. EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan.
Huang SF; Chuang WY; Chen IH; Liao CT; Wang HM; Hsieh LL
Head Neck; 2009 Aug; 31(8):1068-77. PubMed ID: 19360742
[TBL] [Abstract][Full Text] [Related]
33. Thymic carcinoma: is it a separate entity? From molecular to clinical evidence.
Marx A; Rieker R; Toker A; Länger F; Ströbel P
Thorac Surg Clin; 2011 Feb; 21(1):25-31. v-vi. PubMed ID: 21070984
[TBL] [Abstract][Full Text] [Related]
34. Systemic treatment of advanced thymic malignancies.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
[TBL] [Abstract][Full Text] [Related]
36. COX-2 upregulation in thymomas and thymic carcinomas.
Rieker RJ; Joos S; Mechtersheimer G; Blaeker H; Schnabel PA; Morresi-Hauf A; Hecker E; Thomas M; Dienemann H; Schirmacher P; Kern MA
Int J Cancer; 2006 Nov; 119(9):2063-70. PubMed ID: 16823844
[TBL] [Abstract][Full Text] [Related]
37. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
[No Abstract] [Full Text] [Related]
38. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Giaccone G; Rajan A; Ruijter R; Smit E; van Groeningen C; Hogendoorn PC
J Thorac Oncol; 2009 Oct; 4(10):1270-3. PubMed ID: 20197733
[TBL] [Abstract][Full Text] [Related]
39. Aberrant methylation of tumour-related genes in thymic epithelial tumours.
Hirose Y; Kondo K; Takizawa H; Nagao T; Nakagawa Y; Fujino H; Toba H; Kenzaki K; Sakiyama S; Tangoku A
Lung Cancer; 2009 May; 64(2):155-9. PubMed ID: 18778870
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
